Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
TRUQAP (CAPIVASERTIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
TRUQAP
NDA
Get alerts
CAPIVASERTIB | N218197 | ASTRAZENECA PHARMACEUTICALS LP
2 strengths
7 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
Approvals
Label
Products
Patent Timeline
7 unique patents, 1 exclusivity by expiration date
All strengths
160MG
200MG
Active (7)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
Today
8101623
Mar. 10, 2030
9487525
Apr. 16, 2033
10039766
Apr. 16, 2033
10059714
Oct. 10, 2028
10654855
Oct. 10, 2028
11760760
Oct. 10, 2028
12252495
Oct. 10, 2028
NCE
Nov. 16, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 160MG
RLD
7 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Nov 16, 2023
Patents (7)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8101623
Mar 10, 2030
—
Yes
Yes
U-3762
TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
—
9487525
Apr 16, 2033
—
Yes
Yes
—
—
10039766
Apr 16, 2033
—
—
—
U-3762
TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
—
10059714
Oct 10, 2028
—
Yes
Yes
—
—
10654855
Oct 10, 2028
—
—
—
U-3762
TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
—
11760760
Oct 10, 2028
—
—
—
U-3762
TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
—
12252495
Oct 10, 2028
—
—
—
U-3762
TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY
—
Exclusivities (1)
Code
Date
Status
NCE
Nov 16, 2028
Active
#002 — 200MG
RLD
7 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Nov 16, 2023